Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Fulcrum Therapeutics, Inc.

< Previous 1 2 Next >
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Chief Financial Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces CFO Resignation
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.